Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Hematological Malignancies Market Landscape and Future Outlook

The global market for hematological malignancies (AML, NHL, CLL, and MM) expected to reach $60 billion by 2029, growing with a CAGR of 8.8%, largely driven by high unmet needs, as well as development and commercialization of novel small molecule inhibitors and mega-blockbuster biologics.

  • Other factors driving market growth include growing proportion of deals and collaborations among the industry and academic partners such as increasing number of clinical collaborations for evaluating the combinations of novel therapies, coupled with advancing the co-developed and jointly commercialized products in the hematological malignancies in the past five years.
Hematological Malignancies Market

Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Genomic analysis has greatly influenced the diagnosis and clinical management of patients affected by diverse forms of hematologic malignancies. The hematological malignancy diagnosis ranges from a chronic, slow-progressing condition to a fast growing, frequently fatal disease.

There are three main types of hematologic malignancies: leukemia, lymphoma and myeloma with many subgroups collectively. Some of the most well-studied hematological malignancies include leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma (HL), multiple myeloma, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms. Of these, the most common blood cancer types include non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma (MM).

  • Leukemia begins in early blood-forming cells in the bone marrow, the spongy tissue inside bones.
  • Lymphoma begins in lymphocytes, white blood cells that are part of the lymphatic system. The lymphatic system is part of the immune system and helps fight infection.
  • Multiple myeloma affects the plasma cells in bone marrow. Plasma cells make antibodies that help the immune system fight infections.

In developed countries and developing countries hematological malignancies account for 8-9% of all cancers, being the fourth common cancer in developed countries. In the United States, a newly diagnosed blood cancer patient is reported every three minutes, and new cases of blood cancers account for approximately 10% of all new cancer diagnoses. It is also estimated that 1.3 million people in the US are either living with or are in remission from a blood cancer.

  • According to the American Cancer Society (ACS) in the US the blood cancer estimates for 2022 are:
    • Leukemia
      • About 60,650 new cases of leukemia (all kinds) and 24,000 deaths from leukemia (all kinds)
      • About 20,050 new cases of acute myeloid leukemia (AML). Most will be in adults.
      • About 11,540 deaths from AML. Almost all will be in adults.
    • Non-Hodgkin lymphoma
      • About 80,470 people (44,120 males and 36,350 females) will be diagnosed with NHL. This includes both adults and children.
      • About 20,250 people will die from this cancer (11,700males and 8,550 females).
    • Chronic lymphocytic leukemia
      • About 60,650 new cases of leukemia and about 24,000 deaths from leukemia (all kinds)
      • About 20,160 new cases of CLL
      • About 4,410 deaths from CLL
    • Multiple myeloma
      • About 34,470 new cases will be diagnosed (19,100 in men and 15,370 in women).
      • About 12,640 deaths are expected to occur (7,090 in men and 5,550 in women).

The COVID‑19 pandemic has complicated current healthcare services for cancer patients. Patients with hematological malignancies were specifically vulnerable to SARS‑CoV‑2 infection due to their immunosuppressed status. The COVID‑19 pandemic influenced every step of the assessment and treatment of a hematological malignancy.

  • According to published reports, cancer patients are estimated to be twice as likely to be contaminated with SARS-CoV-2 compared with the general population, and in case of infection, these patients are at higher risk of serious episodes, leading to ICU, invasive ventilation or death, compared with patients without cancer.

Scientific and technological advances have led to a significant improvement in five-year relative survival rates for blood cancers, having more than doubled for lymphoma and more than quadrupled for myeloma and leukemia.

  • The blood cancer therapeutics landscape is changing quickly, with entirely new kinds of treatments are now available. The treatment options may include any combination of bone marrow transplantation, chemotherapy, chimeric antigen receptor (CAR) T-cell therapy, and immunotherapy.
    • Many targeted therapies (e.g., monoclonal antibodies, small molecule inhibitors, etc.) have been approved for blood cancers and some of them have established as the standard of care in specific indications.
  • The global market for hematological malignancies (AML, NHL, CLL, and MM):
    • The global market for acute myeloid leukemia projected to reach $3.2 billion by 2029, expanding at a double-digit CAGR of 15.2% over the forecast period, driven by introduction of premium-priced products and strong pipeline of potential newer drugs.
    • The global market for non-Hodgkin lymphoma anticipated to reach $14.4 billion by 2029, growing at a CAGR of 7.4% over the forecast period, driven largely by high-priced biologic and rich pipeline of targeted therapies.
    • The chronic lymphocytic leukemia has always been considered one of the main forms of leukemia, but this disease is now classified as a type of NHL, called CLL or small lymphocytic lymphoma (SLL).
    • The global market for chronic lymphocytic leukemia estimated to reach $15.2 billion by 2029, expanding at a double-digit CAGR of 12.7% over the forecast period, driven by launch of expensive new therapies for CLL patients with high unmet needs.
    • The global market for multiple myeloma expected to reach $24.1 billion by 2029, declining steadily at a CAGR of 0.1% over the forecast period, driven by patent expiry of costly branded drugs, introduction of generic products, and potential approval of novel therapies.

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com